Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Naoxueping is a traditional Chinese medicine (TCM) preparation developed by Xuanwu Hospital of Capital Medical University for the treatment of acute intracerebral hemorrhage (ICH). It is specifically utilized in the management of spontaneous, non-surgical ICH to facilitate the absorption of intracranial hematomas and reduce perihematomal brain edema. The preparation is typically administered as an adjunct to guideline-recommended standard treatments to enhance neurological recovery and improve clinical outcomes. As a botanical-based therapy, its pharmacological profile involves multi-target modulation of the inflammatory response and vascular integrity following a hemorrhagic event.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Naoxueping.